

Evidence-based COVID-19 ICU Management Guide v2.0

Aims of Management Guide


COVID-19 patients admitted to ICU respond to good quality supportive care. This evidence-based guide aims to highlight unique features of COVID-19 management including:

- Monitoring for secondary complications associated with COVID-19 infection
- Differences in approach to common ICU issues to prevent unnecessary interventions which may put patient and staff at risk

Monitoring for Secondary Complications of COVID-19

Four major complications associated with COVID-19 have been highlighted from the literature:

1. **COVID-19 Associated Coagulopathy (CAC)**
2. **Cytokine Storm/Secondary HLH/Macrophage Activation Syndrome**
3. **Secondary Bacterial Superinfection**
4. **Viral Myocarditis** *(may be seen as part of cytokine storm)



Laboratory Investigations on Admission

- CBC, Urea, Creat, Extended Lytes ($Mg^{2+}/PO_4/iCa^{2+}$), D-Dimer, LFTs (AST, ALT, GGT, ALP, Direct and Total Bili, Alb, LDH), Ferritin, Coagulation Screen (INR/PTT), Fibrinogen, Troponin, Procalcitonin, CRP
 - Blood Cultures x 2
 - NP Swab for Viral PCR (if not already sent) *for all patients*
- AND**
- Tracheal aspirates for Viral PCR (if not already sent) *for intubated patients*

Daily Bloodwork

- CBC, Urea, Creat, Extended Lytes, Coagulation Screen, Fibrinogen

Monday/Wednesday/Friday

- LFTs, (AST, ALT, GGT, ALP, Direct and Total Bili, Alb, LDH), Ferritin, D-Dimer, CRP
- Lipid Profile (LDL, HDL, Triglycerides) if ferritin $>2000ng/mL$ in addition to daily orders
- Reassess frequency of these additional tests after Week One

If increasing leukocytosis ($WCC >10 \times 10^9/L$), clinical concern for bacterial infection AND Temp $>38.5^\circ C$

- Procalcitonin and pan-culture if not already performed in last 24hrs

Features of COVID-19 Complications

CAC

Suspect if:

- INR >1.5
- Degree of PTT rise less than INR rise
- Platelets <100x10⁹/L
- Fibrinogen ≤1.0g/L
- D-Dimer positive



ACTION:

- ✓ Ensure valid Group and Screen available

Cytokine Storm

Suspect if:

- Temperature ≥38.4°C
- Pancytopenia (WCC <4x10⁹/L, Hgb <90g/L, Plts <100x10⁹/L)
- Ferritin >2000mcg/L
- Triglycerides ≥1.5mmol/L
- Fibrinogen ≤2.5g/L



ACTION:

- ✓ Perform HScore (MedCalc)

Secondary Bacterial Infection

Suspect if:

- Increasing WCC (>10x10⁹/L)
- Temperature ≥38.5°C
- Significant clinical change in patient hemodynamics



ACTION:

- ➔ Send Procalcitonin
- ➔ Pan-culture if not done in last 24hrs
- ✓ Start broad-spectrum antibiotics

Viral Myocarditis

Suspect if:

- Significant clinical change in patient hemodynamics
- New heart rhythm



ACTION:

- ➔ Send Troponin and BNP (if raised consider causes e.g. ischemia, PE)
- ❖ Do NOT routinely perform ECG
- ✓ ICU Doctor to consider POCUS TTE

Other Management Considerations

Management of hypotension and/or low urine output:

Efforts should be made to limit fluid administration where possible due to evidence that patients with COVID-19 may develop worse lung injury with positive fluid balance

- ICU doctor to assess need for further investigations for determination of fluid status
- Minimise crystalloid bolus volumes to 250mL aliquots
- Early institution of vasopressors to reduce fluid requirements
- Consider secondary bacterial infection or viral myocarditis (see above)

Management of change in heart rhythm (in otherwise stable patient):

- Do NOT routinely call for 12-lead ECG
- Do NOT routinely retake blood for electrolytes
- ICU Doctor to assess need for further investigations based on bedside ECG monitoring

Tapering of initial antibiotic therapy:

- Review need for antibiotics started on admission with results of procalcitonin and rationalise or stop where possible

Notes on Lab Tests / Rationale and References for

<p>D-Dimer</p> <p><i>Why are we tracking D-Dimer levels?</i></p>	<ul style="list-style-type: none"> Moderate evidence in multiple studies that elevation on admission >1000mcg/L is independent risk factor for mortality¹ <ul style="list-style-type: none"> OR=18.42 (2.64-128.55; p=0.003) 168 Wuhan cases: median level in survivors 610mcg/L (highest level 1290), non-survivors median 2120mcg/L (770-5270)² 449 patients in Wuhan: D-Dimer, prothrombin time were positively, and platelet count was negatively, correlated with 28-day mortality in multivariate analysis (D-Dimer >3000mcg/L 52.4%, P=0.017). Better prognosis with heparin treatment.³
<p>LFTs</p> <p><i>LFTs are abnormal in many patients, why not do them daily?</i></p>	<ul style="list-style-type: none"> Elevation in AST, ALT does not correlate with mortality⁴ Unclear whether a measure of viral load and direct viral liver inflammation or elevations due to drug toxicity, cytokine storm or hypoxemia: seen in 14-53% of patients (2-11% had liver comorbidities)⁵
<p>Ferritin</p> <p><i>Why are we tracking Ferritin levels?</i></p>	<ul style="list-style-type: none"> Conflicting evidence: appears to be higher in more severe cases but not clear if useful predictor of mortality <ul style="list-style-type: none"> Median non-survivors 1435 (728-2000) vs 503 (<920)¹ Correlates with ARDS but not mortality: non-survivors median 1029 (546-2000) vs survivors median 457 (<700)⁶ COVID-19 may precipitate a cytokine storm/secondary HLH syndrome (no clear cases yet due to difficulty in diagnosis)⁷: a ferritin of >2000 (HScore) would raise suspicion of this diagnosis and help to highlight cases who may benefit from immunosuppression
<p>Troponin</p> <p><i>Why do a troponin on admission and not trend it further?</i></p>	<ul style="list-style-type: none"> Prognostic but different assays and normal ranges limit external validity Non-survivors have significantly higher levels but still often within the normal range^{1,4}
<p>Procalcitonin</p> <p><i>Why check a PCT on admission?</i></p>	<ul style="list-style-type: none"> Levels <0.5ng/mL in 95% of patients presenting with Covid-19 and does not correlate with severity of disease (using a primary outcome of death/ventilation/ICU admission)⁹ Consider an alternative diagnosis and prioritise standard sepsis treatment if level >0.5ng/mL Later in course of disease can be used to assess if chance of superadded bacterial infection

References:

- Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*. 10.1016/S0140-6736(20)30566-3.
- Tang N, Li D, Wang X, et al. Abnormal Coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *Journal of Thrombosis and Haemostasis*. 10.1111/jth.14768
- Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *Journal of Thrombosis and Haemostasis*. <https://doi.org/10.1111/jth.14817>
- Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med* (2020). <https://doi.org/10.1007/s00134-020-05991-x>
- Zhang C, Shi L, Wang F, et al. Liver injury in COVID-19: management and challenges. *Lancet Gastroenterology and Hepatology*. [https://doi.org/10.1016/S2468-1253\(20\)30057-1](https://doi.org/10.1016/S2468-1253(20)30057-1)
- Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med*. Published online March 13, 2020. doi:10.1001/jamainternmed.2020.0994
- Mehta P, McAuley D, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. *The Lancet*. [https://doi.org/10.1016/S0140-6736\(20\)30628-0](https://doi.org/10.1016/S0140-6736(20)30628-0)
- Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*. 2020;323(11):1061–1069. doi:10.1001/jama.2020.1585
- Guan W, Ni Z, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *NEJM*. 10.1056/NEJMoa2002032